Clinical trial · Interventional
Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
High concentrations of parathyroid hormone (PTH) are common in patients with hepatocellular carcinoma (HCC). This study is aimed to investigate effects of vitamin D status and its multiple mega-dosage supplementation on PTH and clinical outcomes in HCC patients before and after hepatectomy. It's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. The subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Liver Function | — | UNRESOLVED | — |
| Postoperative Complications | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Other | — | UNRESOLVED |
| Vitamin D | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Vitamin D group
- description
- Oral supplementation of 1,728,000 IU vitamin D3 in 3 days
- interventionNames
- Other: Vitamin D
- type
- PLACEBO_COMPARATOR
- label
- Placebo Group
- description
- Oral supplementation of placebo in 3 days
- interventionNames
- Other: Placebo
Primary outcomes (5)
- measure
- Whether there is an association between 25(OH)D and PTH: positive or negative association , or no association
- timeFrame
- During the study period
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. ≥ 20-year HCC subjects receiving laparoscopic hepatectomy * 2.Sign the informed consent Exclusion Criteria: * 1\. Using estrogen drugs, bisphosphonates, or drugs for bone disease. * 2\. Consume calcium tablets within 2 weeks before operation * 3\. Sarcoidosis, multiple myeloma * 4\. Pregnant women or plan to become pregnant within 3 months after surgery * 5\. Autoimmune hepatitis (AIH) * 6\. Early liver recurrence * 7\. Used to participate in other clinical trials
References
Publications (0)
Data not yet available